International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 5 Sep - Oct 2024, pp: 927-933 www.ijprajournal.com ISSN: 2456-4494

Artificial Intelligence in the field of pharmaceutical Science

Adnan Ahmed, Gopal Maity, Ashifizzaj, Imran Najir

Date of Submission: 10-10-2024 Date of Acceptance: 20-10-2024

ABSTRACT:
This literature survey explores the trans-formative potential of artificial intelligence (AI) in the pharmaceutical industry, especially in drug discovery and development. AI offers significant advantages over traditional methods by analyzing large amounts of data to identify new drug targets, optimize lead compounds, and predict efficacy and safety. The article discusses various AI techniques used throughout the drug development process, from new design to clinical trials. Additionally, it highlights the challenges associated with AI in drug development, such as data quality, model interpretability, and ethical considerations. Finally, the article explores the promising future of AI in pharmaceutical research and development, highlighting its potential to accelerate drug discovery, improve clinical trial design, and ultimately provide delivering more effective and personalized medicines.

I. INTRODUCTION:

Artificial intelligence (AI) is an area of computer science aiming at developing machines which are capable of doing activities that would typically require human intelligence. This includes things like learning, thinking, problem solving, perception, language comprehension, and even certain levels of creativity. For last many decades, scientists, philosophers, and the general public have been attracted by the premise of artificial intelligence, which has its origins in ancient mythology and early computing theory.[1]

Artificial intelligence in the field of pharmaceutical science:

Artificial Intelligence (AI) has transformed the pharmaceutical industry in several ways. AI support for the pharmaceutical industry enhances the product's whole life cycle. AI may be used in pharmaceuticals for anything from product management to medication development. Future AI issues have been discussed, along with corresponding solutions. Now a days public are began to apply AI in their daily life which leads to introduction of AI in the filed of pharmacy due to which more benefits are possible. This review focuses on the significant applications of AI in the pharmaceutical industry, including drug development and discovery, drug re-purposing, increasing pharmaceutical productivity, clinical trials, etc., to name a few. This reduces the workload for humans and expedites the achievement of goals. Crosstalk regarding the instruments and methods used.

The pharmaceutical business has undergone a radical transformation as a result of the acceleration of the pharmaceutical sector's expansion through artificial intelligence-integrated medication research and development. Here, we talk over integration areas, methods and tools for enforcing AI, continuous difficulties, and solutions. Artificial intelligence (AI) has being used more and more in many spheres of society, most notably the pharmaceutical business. The use of AI in the pharmaceutical industry is highlighted in this review, with applications ranging from drug development and discovery to drug re-purposing, increasing pharmaceutical productivity, and clinical trials. These applications not only expedite target achievement but also lessen the workload for humans. We also speak about recurring issues, methods, and cross-talk across the AI tools and strategies. [2]

Artificial Intelligence: networks and tools

AI himself have a various ability such as answering for a query, reasoning, representation solution search. One big part of AI is machine learning ML uses algorithms to find patterns in data that's been sorted.A part of machine learning is deep learning, which uses artificial neural networks (ANNs). These networks are like a bunch of connected computer parts that work like human brain neurons, sending electric signals. ANN have nodes that get input and turn it into output using certain algorithms. There are different types of ANNs like Multi Layer Perceptron (MLP) networks, recurrent neural networks (RNNs), and convolutional neural networks (CNNs). They're trained either with supervision or without supervision. The MLP network finds patterns, helps with optimization, Identifies processes, and controls things. RNNs have loops to remember info, like Boltzmann constants and Hopfield networks .CNNs are systems with connections that help process images and videos, model biological systems, recognize patterns and signals. There are even more complex networks like Kohonen networks, RBF networks, LVQ networks. There are tools made using these networks for AI systems. One example is the International Business Machine (IBM) Watson supercomputer. It's used to analyze medical info and suggest treatment plans for cancer patients. It's also quick at finding diseases – it can spot breast cancer in just 60 seconds[3]

History:

Let's talk about the amazing journey of AI in the field of medicine. It's been quite a ride, so let's break it into bite-sized pieces for you back in the 1950s, AI was just starting out. Think of pioneers like Alan Turing dreaming up intelligent machines. They were trying to solve problems like humans do, using logic and rule-based systems. Fast forward to the 1960s, and we see the rise of "expert systems." These systems were all about capturing human knowledge and putting it into computer programs for medical decisions. Something called MYCIN even showed how AI could diagnose bacterial infections. In the 1970s, computer-aided diagnosis (CAD) systems started helping out with medical imaging. It was a game-changer.

By the 1980s, AI was diving into image recognition algorithms for medical stuff like X-rays, CT scans, and MRIs. Patterns and machine learning really stepped up their game here. Then the 1990s rolled around, and NLP (Natural Language Processing) made it possible for AI to read medical text data. Also, robots started doing surgery with systems like da Vinci Surgical System. AI and robotics were becoming a duo for minimally invasive procedures. The early 2000s brought electronic health records (EHRs) and big data into the mix for even more AI applications. Deep learning (DL), a fancy subset of machine learning, rocked the world of medical image analysis and disease diagnosis. Personalized medicine became a hot topic as AI helped tailor treatments based on individual traits and genetic data. This journey through history shows how far AI has come in medicine. We've gone from simple rule-based systems to super cool deep learning algorithms that have boosted health care outcomes and personalized treatment plans in a big way. Pretty awesome stuff[4].

Areas which are managed by the artificial intelligence:

De novo drug design with artificial intelligence

De novo design, or creating new molecular entities with desired pharmacological qualities from scratch a complex computer-assisted process. Drug development is challenging due to the large number of drug-like compounds. De novo molecule creation can lead to combinatorial explosion due to the numerous atomic kinds and molecular topologies available . De novo design techniques can be ligand-based, structure-based, or a combination of the two, dependent on the information provided.. Ligand-based techniques fall into two primary categories: (i) Rule-based techniques utilize building rules to assemble molecules from a collection.[5,6] There are two types of construction methods: "building blocks" (reagents or molecular fragments) and "rule-free" (no specific rules). The Topliss scheme is a precursor to modern rule-based de novo design. It involves the step-by-step synthesis of analogs of an active lead chemical to enhance potency.

Modern techniques to molecular optimization rely on specific transformations, such as matched molecular pairings or rules-of-thumb for functional group and framework change . Synthesis-oriented techniques incorporate guidelines for building block assembly and ligand production. These approaches are useful, such as TOPAS.[6-7] Several different architectures have been implemented that are capable of generating valid and meaningful new structures. These methods can be used to explore new chemical spaces, with the resulting molecules having a property distribution similar to the training space. The first forward applications of the method have been successful, with molecules exhibiting the desired activity. Nevertheless, further experience needs to be gained regarding the size of the chemical space explored and the chemical feasibility of the proposed molecules[8,9,10]

AI in drug discovery

The method of medicate plan and advancement points to find and upgrade sedate candidates for treating illnesses. Counterfeit insights (AI) plays a pivotal part in this prepare by utilizing natural information from genomics, proteomics, and metabolic to distinguish potential helpful targets such as proteins, receptors, or chemicals included in illness instruments. AI encourages the virtual screening of tremendous chemical compound databases to pin point promising candidates for advance inquire about.

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 5 Sep - Oct 2024, pp: 927-933 www.ijprajournal.com ISSN: 2456-4494

Through strategies like structure-activity relationship (SAR) investigation, AI predicts how changes in chemical structures can influence a compound's organic movement, supporting in optimizing its strength and security profile. AI calculations can advance foresee potential medicate poisonous quality by analyzing past harmfulness information and chemical structures, in this way making a difference analysts recognize and dispense with compounds with safety concerns early within the advancement prepare. Also, AI helps in clinical considers by optimizing understanding choice based on statistic and bio-marker information, which improves trial plan and increments the probability of effective results. [11,12,13]

The method of applying AI calculations in medicate disclosure includes a few consecutive steps to guarantee compelling modeling. At first, characterizing the issue space is significant, taken after by planning the essential information. The AI design is at that point planned, with particular choices made based on whether the assignment is discriminative or generative. For discriminative errands, calculations like SVM, RF, and ANNs are common, whereas generative errands may utilize models such as DBM, DBN, GAN, VAE, or AAE, regularly utilizing ANNs for their flexibility. Hyper parameters are balanced in like manner, shifting by calculation sort. Once the engineering is sketched out, information arrangement starts, guaranteeing quality and adequacy. Show preparing and evaluation follow, pointing to play down forecast mistake and accomplish a demonstrate competent of communicating connections inside atomic information. Persistent change includes refining information quality and understanding, basic for optimizing AI show execution in medicate revelation**.** [14]

The medicate disclosure and improvement handle, as gritty in various considers and examined over writing references, ranges a few a long time from introductory target disclosure to FDA endorsement and past, including considerable costs and time. To address these challenges, there's a squeezing got to assist this handle and decrease related costs. Counterfeit insights (AI), including machine learning and profound neural systems, rises as a essential innovation balanced to revolutionize clinical investigate. AI guarantees to upgrade sedate disclosure effectiveness by optimizing different stages such as picture investigation, electronic well being records administration, and work flow streamlining. It is anticipated to increase conventional strategies by encouraging sedate plan, union, screening, and decision-making, possibly relieving the tall costs and long timeline regularly related with sedate improvement. This crossing point of AI and biomedical sciences not as it were points to move forward viability and security profiles but too looks for to revolutionize restorative techniques like quality treatment and immunization plan, eventually progressing open well being results and changing the scene of sedate revelation and improvement. [15]

AI in medicine:

AI is broadly connected in health care past medicate disclosure, enveloping assignments such as online arrangement planning, digitalizing restorative records, observing medicate dosages, and encouraging online check-ins at restorative offices. It plays a significant part in screening existing solutions for viability against maladies like COVID-19, which bolsters the progression of exactness pharmaceutical. Stanford University's Association in AI-assisted care (PAC) utilizes numerous sensors to help ICU patients. AI and machine learning tools improve sedate advancement by extending our understanding of sedate properties and patient-specific components in treatment. [16]The passage talks about the transformative potential of AI in medication, especially in analyzing endless data sets from inquire about and clinical settings to make strides effectiveness and reveal experiences past conventional strategies. In spite of promising progressions, challenges like systemic dangers, moral concerns with respect to inclination in information and calculations, and the require for thorough assessment over different understanding bunches stay critical. Whereas AI appears guarantee in regions such as cancer location, its integration into clinical hone requires cautious approval and thought of its affect on understanding care. The section underscores the progressing wrangle about encompassing AI's part in health care and highlights the need for adjusted execution and proceeded investigate**.** [15,17]

AI in pharmacovigilance and drug safety

Pharmacovigilance, which points to distinguish and screen the security profile of drugs, is an fundamental portion of medicate improvement and post-marketing reconnaissance. A powerful device for expanding pharmacovigilance and sedate security activities is counter sights (AI). Antagonistic occasion recognizable proof, flag investigation, and hazard evaluation are fair a few of the pharmacovigilance capacities that can be upgraded by utilizing AI calculations and strategies. An diagram of AI's work in pharmacovigilance and medicate security is given underneath

Adverse Event Detection:

AI frameworks can find and categories antagonistic occasions related to medicine utilization by examining large-scale health care information, counting electronic well being records, social media posts, and online gatherings. Unstructured information may be extricated and dissected utilizing Normal Dialect Preparing (NLP) methods, making it less demanding to naturally discover hurtful events that are detailed in content sources. This helps in the provoke location of conceivable pharmaceutical security issues.

Signal detection and analysis

The location of conceivable security cautions from vast volumes of information is made less demanding by AI frameworks. AI can distinguish designs and connections that will point to already unidentified medicine security dangers by dissecting organized and unstructured information sources, counting unconstrained detailing databases, scholastic writing, and electronic well being records. Mechanized flag acknowledgment and prioritization is made conceivable by machine learning methods, which bolsters proactive hazard administration and administrative decision making .

Pharmacovigilance Information Administration:

By using AI methods, pharmacovigilance information dealing with strategies may be made more proficient and exact. AI-powered frame works that mechanize the classification and categorization of negative occasions can move forward consistency and decrease manual work. AI calculations may evaluate and combine information from numerous sources, giving a comprehensive picture on pharmaceutical security profiles and encouraging progressed decision-making

Prescient Analytics and Hazard Evaluation:

AI may be utilized to expect and assess pharmaceutical security risks. AI calculations can distinguish individuals who may be more inclined to dangerous medicine reactions by looking at understanding characteristics, hereditary profiles, and other related information. This advances customized medication techniques, empowering restorative suppliers to tailor treatment programs to particular patients' needs and diminish any threats .The utilize of AI in pharmacovigilance and sedate security incorporates a awesome bargain of guarantee to improve the recognizable proof, assessment, and treatment of antagonistic medicate responses. Be that as it may, to guarantee the proficient and ethical application of AI in this industry, issues counting information quality, calculation openness, and lawful concerns must be tended to. To completely use AI in pharmacovigilance and make strides understanding security, it is significant for administrative offices, AI masters, and those working within the health care industry to work together on progressing investigate ventures. [18]

Pharmacovigilance centers on checking, identifying, and anticipating drug-related antagonistic impacts, a basic assignment improved by progressed AI strategies such as machine learning and profound learning. Generative ill-disposed systems are utilized to form unused chemical particles with particular properties, whereas the FDA has issued rules for AI-driven restorative gadget security. AI essentially impacts sedate security experts by progressing their capacity to handle person quiet security information, known as person case security reports (ISCRs). Machine learning strategies streamline decision-making, making medicate security appraisals more productive and precise. By and large, AI in pharmacovigilance optimizes operations, improves dataset administration, and refines investigations of sedate harmfulness and security.[16,19,20]

AI in clinical and per-clinical trial

The article examines AI's transformative affect on clinical trials, improving effectiveness and understanding results. AI analyzes endless data sets to anticipate treatment reactions, distinguish unfavorable occasions, and optimize trial plan by stratifying understanding populaces based on socioeconomic, hereditary qualities, and therapeutic history. Virtual trials and advanced twins mimic medicine responses, lessening dependence on broad human trials. AI-driven wearable tech empowers real-time persistent observing, supporting early mediation and endpoint evaluation. By joining genomic information and electronic records, AI distinguishes bio-markers for personalized medicines and bolsters evidence-based decision-making for pharmaceutical determination and dosage optimization. In general, AI revolutionizes clinical trials by improving

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 5 Sep - Oct 2024, pp: 927-933 www.ijprajournal.com ISSN: 2456-4494

security, exactness, and information investigation capabilities.[18]

Foreseeing conceivable reactions to a sedate could be a basic step in a sedate plan pipeline. Likeness or feature-based machine learning strategies can be utilized to foresee the reaction of a medicate on person cells and the viability of a drug-target interaction by authoritative fondness or free vitality of official. Likeness strategies expect that comparative drugs act on comparable targets , whereas feature-based strategies discover person highlights of drugs and targets and bolster the drug-target highlight vector to the classifier. Profound learning-based strategies, such as Deep conv-DTI and deep affinity are cases strategies, where the inserting of drugs and targets are learned utilizing convolution and consideration instrument. AI-based strategies can help in selecting potential patients for per-clinical trials by recognizing pertinent human-disease bio- markers and expecting potential poisonous or superfluous side impacts and by sifting a high dimensional set of clinical factors to choose a cohort of patients. AI can moreover offer assistance in anticipating the result of clinical trials well ahead of the genuine trial minimizing the chance of any hurtful impact on patients [21]

Challenges

Current medicinal chemistry methods often rely on inefficient, goal-directed approaches and extensive testing procedures that are time-consuming, costly, and often produce inaccurate results. Artificial intelligence offers promising solutions through a variety of algorithms, including supervised and unsupervised learning, reinforcement learning, and evolutionary or rule-based methods. By analyzing vast data sets, AI can predict the efficacy and toxicity of pharmaceutical compounds more accurately and efficiently than traditional methods. Moreover, AI enables the identification of new drug targets, going beyond traditional approaches. This transformative potential could lead to the development of more effective medicines, overcoming the limitations of trial and error, and improving the overall efficiency of drug discovery.[22]

AI in drug development has several obstacles, including different data representation (Such as molecular graphs), labeling inequalities caused by contextual factors like as dosage and patient characteristics, and the dynamic behavior of proteins and chemicals across biological settings. The repeatability dilemma in deep learning derives from its sensitivity to initialization. Biological data sets are complicated and unbalanced, necessitating strong learning paradigms and assessment measures. Reinforcement learning guides molecules across the chemical space to achieve optimal design. However, the effectiveness of AI in health care is hampered by data representation challenges and the black-box nature of models. To address these issues, interpretable models and a thorough grasp of biological dynamics are required for accurate data exploitation and successful drug development.[21]

Computer-aided molecular design relies on property prediction models using structural descriptors like bonds and molecular geometry. Challenges include parameter uncertainty and real-time property prediction. QSAR/QSPR methods handle complex systems but struggle with spatial orientation in 2D models. Computational complexity arises from non-linear models and vast search spaces. Drug discovery methods like structure based drug design (SBDD) such as NMR, X-ray, docking and ligand based drug discovery (LBDD) such as based on known binders use molecular modeling to predict binding affinity, addressing drug design complexities effectively.[16]

Future aspect:

Advances in AI, particularly deep learning and specialized technology, have us hired in a new age of drug development. AI excels at target selection, lead optimization, and predicting pharmacokinetics and toxicity. Despite advances in areas such as image recognition, acquiring high-quality, particular data for pharmaceutical AI applications remains difficult. [14]

Implementing artificial intelligence in precision medicine for activities such as illness detection and therapy prediction presents considerable obstacles. These include assuring high-quality data to prevent errors caused by noisy or biased inputs. Generalization across various populations is crucial, since differences in data distribution between areas or hospitals might have an impact on model effectiveness. Addressing bias in AI models based on patient demographics necessitates thorough validation against real world data. Furthermore, the quality and reliability of ground truth data are critical when employing molecular bio-markers to predict therapy responses. Overcoming these challenges is critical for AI to improve health care outcomes and build confidence in its clinical applications [15]

We have explored how artificial intelligence tools and techniques can be used at each stage of the drug development process, starting from the discovery of a new molecule to its clinical trial management, subsequent manufacturing, quality control aspects, and product management. Unlike the traditional trial-and-error method of drug delivery system development, which requires a lot of time, funds, and efforts, AI-based development approaches tend to accelerate the development process in a relatively efficient and time-saving manner.[23] Humans are no longer viewed as the most advanced machines. The human brain, the most sophisticated network of knowledge, strives to be more efficient than humans in doing tasks and has made significant progress in this regard. Artificial intelligence is becoming increasingly important in the pharmaceutical sector and health care.[24]

II. CONCLUSION:

The rise of artificial intelligence (AI) has revolutionized the pharmaceutical industry, changing the way drugs are discovered and developed. AI provides a powerful set of tools to overcome the limitations of traditional methods, leading to a more efficient and effective drug development process. Here are the key takeaways from this passage on the impact of AI in the field of pharmaceutical Science.

Increased efficiency AI streamlines various stages of drug development, Targeting and optimizing leads for clinical trial design and pharmacovigilance. This reduces time and costs compared to traditional methods. Improved accuracy AI algorithms can analyze large data sets to predict efficacy, toxicity, and patient response with greater accuracy than traditional methods. Personalized Medicine AI facilitates the development of personalized medicine by identifying bio-markers and tailoring treatments to individual patients. New Drug Discovery AI can explore new chemical spaces and identify new drug targets, leading to the discovery of more effective treatments Data Quality and Biased The success of AI models depends on high-quality, unbiased data. It is important to ensure data quality and address potential biases in algorithms. Model Interpretability Understanding how AI models make their predictions is essential to building trust and ensuring precision medicine development. Ethical Considerations Data privacy, algorithmic fairness, and job mobility in the pharmaceutical industry need to be carefully considered.

REFERENCES:

[1]. Dasta JF. Application of artificial intelligence to pharmacy and medicine. Hosp Pharm 1992;27:312-5, 319-22.

[2]. Anita IoanaVisan and Irina Negut, Referring fromIntegrating Artificial Intelligence for drug Discovery in the Context of revolutionizing Drug Delivery. LifeYear 2024, 14, 233.https://doi.org/10.3390/life14020233

[3]. DebleenaPaulz , Gaurav Sanapz , SnehalShenoyz , DnyaneshwarKalyane, Kiran Kalia and Rakesh K. TekadeReferring from Artificial intelligence in drug discovery and development , Drug Discovery Today , Volume 26, Number 1 , YearJanuary 2021, Page number 81.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577280/

[4]. Anita IoanaVisan and Irina Negut, Referring from Integrating Artificial Intelligence for drug Discovery in the Context of revolutionizing Drug Delivery. Life Year 2024, 14, 233. Page number 1 to 2. https://doi.org/10.3390/life14020233

[5]. José Jiménez-Luna, Francesca Grisoni, Nils Weskamp&Gisbert Schneider Artificial intelligence in drug discovery: recent advances and future perspectives Published online: 02 Apr 2021. To link to this article: https://doi.org/10.1080/17460441.2021.1909567

[6]. Dobson CM. Chemical space and biology. Nature. 2004;432 (7019):824–828.

[7]. Lipinski C, Hopkins A. Navigating chemical space for biology and medicine. Nature. 2004;432(7019):855–861.

[8]. Gerhard Hessler 1,* and Karl-Heinz Baringhaus 2, Artificial Intelligence in Drug Design,Molecules **2018**, 23(10), 2520. **https://doi.org/10.3390/molecules23102520**

[9]. Schneider, P.; Schneider, G. De Novo Design at the Edge of Chaos. J. Med. Chem. 2016, 59, 4077–4086. [CrossRef] [PubMed]

[10]. Merk, D.; Friedrich, L.; Grisoni, F.; Schneider, G. De Novo Design of Bioactive Small Molecules by Artificial Intelligence Daniel. Mol. Inf. 2018, 37, 1700153. [CrossRef] [PubMed]

[11]. Omega John Unogwu1,2*, , Mabel E. Ike3, , OpkanachiOmatule Joktan4, Employing Artificial Intelligence Methods in Drug Development: A ,New Era in Medicine,20 Oct 2023, https://www.researchgate.net/publication/374921377

[12]. M. Nascimben and L. Rimondini, "Molecular Toxicity Virtual Screening Applying a Quantized Computational SNNBased Framework," Molecules, vol.28, no.3, pp.1-19, January 2023. https://doi.org/10.3390/molecules28031342

[13]. X. He, X. Liu, F. Zuo, H. Shi, and J. Jing, "Artificial intelligence-based multi-omics analysis fuels cancer precision medicine," Seminars in Cancer Biology, vol.88, pp.187-200, January 2023. https://doi.org/10.1016/j.semcancer.2022.12.009

[14]. Xin Yang,† Yifei Wang,† Ryan Byrne,‡ Gisbert Schneider,*,‡ and Shengyong Yang*,†, Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery, DOI: 10.1021/acs.chemrev.8b00728

[15]. Claudio Carini1,2* and Attila A. Seyhan3,4,5,6*,Tribulations and future opportunities for artifcial intelligence in precision medicine, Carini and Seyhan Journal of Translational Medicine (2024) 22:411 https://doi.org/10.1186/s12967-024-05067-0

[16]. Anushree Tripathi1,*, Krishna Misra2,*, Richa Dhanuka1 and Jyoti Prakash Singh1, Artificial Intelligence in Accelerating Drug Discovery and Development. https://www.researchgate.net/publication/362449953

[17]. Li R, Kumar A, Chen JH. How chatbots and large language model artifcial intelligence systems will reshape modern medicine: fountain of creativity or pandora's box? JAMA Intern Med. 2023;183:596–7.

[18]. Ram BabuSharma,SwatiKaushal,AmardeepKaur,DivyaDhawalBhndari, Artificial intelligence: recent advancementsin drug design and development. https://www.researchgate.net/publication/379955831

[19]. Dumontier M, Villanueva-Rosales N. Towards pharmacogenomics knowledge discovery with the semantic web. Brief Bioinform. 2009 Mar;10(2):153-63. doi: 10.1093/bib/bbn056, PMID 19240125

[20]. Scheibelhofer O, Balak N, Wahl PR, Koller DM, Glasser BJ, Khinast JG. Monitoring blending of pharmaceutical powders with multipoint NIR spectroscopy. AAPS PharmSciTech. 2013 Mar;14(1):234- 44. doi: 10.1208/s12249-012-9910-4, PMID 23263752. PMCID PMC3581660

[21]. Rizwan Qureshi a,e,∗, Muhammad Irfan b, TaimoorMuzaffarGondal c, Sheheryar Khan d, Jia Wu e, Muhammad Usman Hadi f, John Heymach g, Xiuning Le g, Hong Yan h, TanvirAlam a,∗∗ AI in drug discovery and its clinical relevance. https://doi.org/10.1016/j.heliyon.2023.e17575

[22]. Alexandre Blanco-González 1,2,3 , Alfonso Cabezón 1,2, Alejandro Seco-González 1,2, Daniel Conde-Torres 1,2 , Paula Antelo-Riveiro 1,2 , ÁngelPiñeiro 2,* and Rebeca Garcia-Fandino 1,* The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies, Published: 18 June 2023, Pharmaceuticals 2023, 16, 891. https://doi.org/10.3390/ph16060891

[23]. Noorain1 , Varsha Srivastava2 , Bushra Parveen3 and RabeaParveen, Artificial Intelligence in Drug Formulation and Development: Applications and Future Prospects. DOI: 10.2174/0113892002265786230921062205

[24]. Manish Vyas1 , Sourav Thakur2 , Bushra Riyaz3 , Kuldeep K Bansal4 , Bhupendra Tomar2 , Vijay Mishra3 * Artificial Intelligence: The Beginning of a New Era in Pharmacy Profession. https://www.researchgate.net/publication/327061371